Photoreactive 111In-cyclodextrin inclusion complex: a new heterobifunctional reagent for antibody labeling |
| |
| Affiliation: | 1. Department of Physics, Karpagam Academy of Higher Education, Eachanari Post, Pollachi Main Road, Coimbatore 641 021, Tamilnadu, India;2. Department of Physics, Sri Ramakrishna Mission Vidyalaya College of Arts and Science, Coimbatore 641 020, Tamilnadu, India;1. School of Mechanical and Power Engineering, East China University of Science and Technology, Shanghai 200237, China;2. Center for Human Tissues and Organs Degeneration, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China;3. School of Physics and Astronomy, Yunnan University, Kunming 650091, China;1. Y.B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Aurangabad 431001, M.S., India;2. Department of Biotechnology, Savitribai Phule Pune University, Pune 411007, M.S., India;3. Shivaji University, Vidyanagar, Kolhapur 416 004, M.S., India;4. Department of Molecular Genetics & Dental Research Institute, School of Dentistry, Seoul National University, Seoul 110-749, Republic of Korea |
| |
| Abstract: | The compound of interest, N-5-azido-2-nitrobenzoylaminomethyl-111In-acetylacetone-α-cyclodextrin (CD) (V) was synthesized by the selective tosylation of α-CD to form 6-tosyl-6-deoxy-CD, which was then reacted with NaN3 to form 6-azido-6-deoxy-CD (II). This was followed by catalytic hydrogenation to yield III. Compound III and 111In-acetylacetone were mixed to form an inclusion complex, which was then reacted with N-5-azido-2-nitrobenzoyloxysuccinimide to yield compound V. Anti-melanoma MAbTP41.2 was added to compound V, followed by immediate photoreactivation labeling by u.v. light at 320 nm. The final product VI was purified from a Sephadex G-50 column. 111In-DTPA-MAbTP41.2 was also prepared as a control.Immunoreactivity via the cell-binding assay of VI was 87%, compared with 57% by the BADTPA method. Biodistribution in non-tumor rats yielded a liver concentration in %ID/g of 3.5, 1.7 and 1.0 for compound VI, compared to the 5.5, 5.2 and 3.1 for the BADTPA compound, at 4, 24 and 48 h post-injection, respectively. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
